Canadian Cardiovascular Society

CCS Research Awards

CCS-HLS Atherosclerosis Research Award

The Canadian Cardiovascular Society and HLS Therapeutics are proud to support the 2022 CCS/HLS Atherosclerosis Research Award. Open to Canadian MDs in the first 5 years of their first clinical appointment in an academic department for a research project on the topic of atherosclerosis. Priority will be given to research that has the potential to advance clinical knowledge of atherosclerosis process linked to inflammation, membrane stability and biomarkers.

Application deadline EXTENDED: Monday, September 20th, 2021 at 11:59 AM EST


CCS-Bayer Cardiovascular Research Award

The CCS − Bayer Cardiovascular Research Award is open to Canadian clinical trainees (PGY 4-6) undertaking a research project on any topic related to thrombosis, anticoagulation, stroke, heart failure or atrial fibrillation — particularly research that has the potential to advance knowledge about or improve the care of patients at risk for vascular, thrombotic or embolic events.

Application deadline EXTENDED: Thursday, September 9th, 2021 at 11:59 AM EST


CCS/HSRLCE/BI-Lilly Cardiometabolic Research Award

The Canadian Cardiovascular Society (CCS), Heart & Stroke / Richard Lewar Centre of Excellence in Cardiovascular Research (HSRLCE), and the BI-Lilly Alliance are proud to support the 2021 CCS/HSRLCE/BI-Lilly Cardiometabolic Research Award. This award is intended for trainees, residents and early career members for a research project on any topic related to cardiometabolic disease.

Application deadline EXTENDED: Thursday, September 9th, 2021 at 11:59 AM EST


BMS-Pfizer AF Research Award

Sponsored by the BMS-Pfizer alliance, the AF (Atrial Fibrillation) Research Awards support excellence in AF research and support promising Canadian early career researchers with an interest in AF.

Application deadline extended: TBD


CCS/Pfizer ATTR-CM Research Fellowship Award

This is a salary award where the purpose is to foster the growth of peer-reviewed Canadian research in the area of Transthyretin Amyloid Cardiomyopathy (ATTR-CM), with a focus on excellence and support for early career Canadian researchers familiar with diagnosing and treating patients with ATTR-CM who are looking to establish an independent research career.

Application deadline extended: TBD


CCS COVID-19 Challenge for Canada Initiative (CCS-C3I)

As the prevalence and outcomes of cardiovascular complications of COVID-19 remain poorly understood and uncharacterized, the aim of C3I  is to empower the CCS clinician-scientist community to be prepared to harness emerging large-scale funds. By fostering multisite cardiovascular research across Canada, our CV community will be at the forefront of readiness for large-scale, CVD-related COVID-19 disease initiatives.

Application deadline: TBD

Back to top